- Home
- AACG vs FEMY Comparison
AACG vs FEMY Comparison
Compare AACG & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- FEMY
- Stock Information
- Founded
- AACG 1999
- FEMY 2004
- Country
- AACG China
- FEMY United States
- Employees
- AACG N/A
- FEMY N/A
- Industry
- AACG Other Consumer Services
- FEMY Medical/Dental Instruments
- Sector
- AACG Real Estate
- FEMY Health Care
- Exchange
- AACG Nasdaq
- FEMY Nasdaq
- Market Cap
- AACG 28.2M
- FEMY 28.3M
- IPO Year
- AACG N/A
- FEMY 2021
- Fundamental
- Price
- AACG $0.77
- FEMY $0.98
- Analyst Decision
- AACG
- FEMY Strong Buy
- Analyst Count
- AACG 0
- FEMY 3
- Target Price
- AACG N/A
- FEMY $8.67
- AVG Volume (30 Days)
- AACG 11.4K
- FEMY 557.5K
- Earning Date
- AACG 08-06-2025
- FEMY 08-07-2025
- Dividend Yield
- AACG N/A
- FEMY N/A
- EPS Growth
- AACG N/A
- FEMY N/A
- EPS
- AACG N/A
- FEMY N/A
- Revenue
- AACG $37,997,003.00
- FEMY $1,699,232.00
- Revenue This Year
- AACG N/A
- FEMY $231.84
- Revenue Next Year
- AACG N/A
- FEMY $245.28
- P/E Ratio
- AACG N/A
- FEMY N/A
- Revenue Growth
- AACG 21.24
- FEMY 61.97
- 52 Week Low
- AACG $0.50
- FEMY $0.69
- 52 Week High
- AACG $1.10
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- AACG 35.81
- FEMY 55.24
- Support Level
- AACG $0.75
- FEMY $0.85
- Resistance Level
- AACG $0.86
- FEMY $1.10
- Average True Range (ATR)
- AACG 0.04
- FEMY 0.08
- MACD
- AACG -0.01
- FEMY 0.02
- Stochastic Oscillator
- AACG 11.71
- FEMY 63.50
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.